1. Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? 
Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana Margarida Medeiros, MSc, Cibelle Mariano, MSc, Goreti Lobarinhas, MD, PhD, António Guerra, MD, PhD, Helena Mansilha, MD, PhD, Helena Cortez-Pinto, MD, PhD, Mafalda Bourbon, PhD 
Journal of Clinical Lipidology 
Volume 11, Issue 2, Pages e2 (March 2017)
DOI: /j.jacl
Copyright © 2017 National Lipid Association Terms and Conditions

2. Figure 1
Pedigrees of families (A, B and C) of the 3 index cases with c.894G>A. Filled boxes, homozygotes; dotted boxes, heterozygote carriers; open boxes, not tested; N, negative for family mutation. Index cases are signaled with an arrow. Below the symbols are indicated: generation number, age (years), TC, total cholesterol (mg/dL); LDL-C, low-density lipoprotein cholesterol (mg/dL); HDL-C, high-density lipoprotein cholesterol (mg/dL); TG, triglycerides (mg/dL); AST, aspartate transaminase (U/L); ALT, alanine transaminase (U/L); LAL, lysosomal acid lipase activity (nmol/punch/h). †, cause (when available) and age of death.
Journal of Clinical Lipidology  , e2DOI: ( /j.jacl )
Copyright © 2017 National Lipid Association Terms and Conditions

3. Figure S1
Diagram of clinical criteria distribution in the e_COR sample (n = 258) revealing the complex phenotype of these individuals. FH, familial hypercholesterolemia (n = 24); FCHL, familial combined hyperlipidemia (n = 34); LALD, clinical suspicion of lysosomal acid lipase deficiency (n = 16); steatosis (n = 231).
Journal of Clinical Lipidology  , e2DOI: ( /j.jacl )
Copyright © 2017 National Lipid Association Terms and Conditions